Preclinical evaluation of a semi-automated and rapid commercial electrophoresis assay for von Willebrand factor multimers by Pikta, Marika et al.
J Clin Lab Anal. 2018;32:e22416.	 wileyonlinelibrary.com/journal/jcla	 	 | 	1 of 9
https://doi.org/10.1002/jcla.22416
© 2018 Wiley Periodicals, Inc.
1  | INTRODUC TION
von Willebrand factor (VWF) is a large multimeric adhesive sialo-
glycoprotein1,2 that mediates platelet adhesion to sub- endothelium 
structures and acts as a factor VIII (FVIII) carrier molecule, thus stabi-
lizing the procoagulant activity of FVIII in the circulation.1-5 The pro-
tein is synthesized by endothelial cells and megakaryocytes4,6-8 as a 
polypeptide and is composed of identical monomers that assemble 
into a series of multimers. The multimer organization is critical for 
the function of VWF.4 Multimers may range in size from 500 kDa 
to	˃20	000	kDa7 and are usually classified into categories according 
to the number of multimers (dimers) and size: low- molecular- weight 
(LMW, 1- 5 dimers, 500- 2500 kDa), intermediate- molecular- weight 
(IMW, 6- 10 dimers, 3000- 5000 kDa), high- molecular- weight (large) 
(HMW, 11- 20 dimers, 5500- 10 000 kDa), and ultra- high- molecular- 
weight (ultra- large) (UHMW, >20 dimers, up to 20 000 kDa) forms.4,7 
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Background: The von Willebrand factor (VWF) multimer test is required to correctly 
subtype qualitative type 2 von Willebrand disease (VWD). The current VWF mul-
timer assays are difficult, nonstandardized, and time- consuming. The purpose of this 
study was to evaluate the clinical utility of the commercial VWF multimer kit by Sebia 
(Lisses, France), an electrophoresis technique yielding same- day results.
Methods: Ten healthy volunteer plasma samples, in- house reference plasma (IRP) 
and commercial normal plasma (CNP) samples, 10 plasma samples from patients with 
a	known	VWD	type,	1	hemophilia	A	plasma	sample,	and	7	external	quality	assurance	
(EQA)	 samples	were	analyzed	using	 the	 commercial	VWF	multimer	kit.	Additional	
coagulation	testing	included	measurements	of	VWF	antigen	(VWF:Ag),	VWF	activity	
(VWF:Ac),	and	FVIII	activity	(FVIII:C).
Results: The CNP results revealed a relative loss of the highest molecular weight 
multimers; therefore, IRP was preferred as the reference sample. The interpretations 
of 10 patients with a known VWD type could be successfully reproduced and agreed 
with	previous	VWF	multimer	 results.	 In	all	EQA	surveys,	 the	multimer	 results	and	
final VWD diagnosis agreed with expert opinion.
Conclusions: The VWF multimer assay by Sebia is easy to perform and can be suc-
cessfully implemented in any clinical laboratory for second- stage evaluation of VWD. 
The resolution power of multimer distribution is adequate to correctly classify VWD 
types	1,	2A,	2B,	and	3.
K E Y W O R D S
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UHMW multimers do not typically circulate in blood because of rapid 
proteolysis by the disintegrin and metalloproteinase with a throm-
bospondin	 type	 1	motif,	 member	 13	 (known	 as	 ADAMTS13)	 that	
cleaves UHMW forms into smaller multimers soon after secretion.4
von Willebrand disease (VWD) is the most common congenital 
bleeding disorder, with a worldwide prevalence of 1%.3,7,8 The cur-
rent classification of VWD variants by the International Society on 
Thrombosis and Haemostasis (ISTH)9 recognizes six different types, 
reviewed with updates elsewhere.1,4,5,7 The diagnosis of VWD 
is aided by good correlation between the clinical picture and tra-
ditional	 (screening)	 assays,	 such	 as	 FVIII,	 VWF	 antigen	 (VWF:Ag),	
VWF	 activity	 (VWF:RCo	 or	 alternatively	 VWF:Ac),3 and, in some 
cases,	the	collagen	binding	capacity	of	VWF	(VWF:CB).10,11 Classical 
screening assays are highly heterogeneous in terms of method-
ology and diagnostic efficacy10; thus, they may lead to over- , un-
der- or misdiagnosis7 and inadequate or inappropriate treatment of 
affected patients.12 Therefore, additional confirmatory VWD tests, 
such	as	VWF	multimers,	are	needed	to	distinguish	type	2A	and	2B	
VWD from type 2M (or type 1) VWD12,13 and diagnose acquired 
VWD. However, multimer analysis is currently performed only by 
a limited number of expert laboratories because it is technically dif-
ficult, laborious, nonstandardized, and time- consuming.14 Indeed, a 
high proportion of laboratories generate unreliable VWF multimer 
results15-17 using in- house assays. To overcome technical difficulties 
and help in the standardization of the method, Sebia (Lisses, France) 
developed a simplified, same- day results semi- automated assay 
(Hydragel 5 von Willebrand multimers) to visualize VWF multimers. 
The purpose of our study was to evaluate the usefulness and fitness 
for clinical purpose of this newly available commercial agarose gel 
electrophoresis technique.
2  | MATERIAL S AND METHODS
2.1 | Patients and samples
Four targets for the evaluation of the VWF multimer pattern were 
selected as follows: (i) 10 healthy volunteer plasma samples; (ii) in- 
house reference plasma (IRP) samples and commercial lyophilized 
pooled	 normal	 plasma	 (CNP)	 samples	 (Diagnostica	 Stago	 S.A.S.,	
Asnières	 sur	 Seine,	 France);	 (iii)	 10	 plasma	 samples	 from	 patients	
with	known	VWD	type	1,	type	2	(subtypes	2A,	2B,	2N),	or	type	3,	
among whom 9 patients were from Finland and 1 was from Estonia, 
plus	one	hemophilia	A	patient	was	selected;	and	(iv)	7	external	qual-
ity	 assurance	 (EQA)	 samples	 from	 the	 “von	Willebrand	Factor	 pa-
rameters”	survey	provided	by	the	ECAT	Foundation	 (Voorschoten,	
the Netherlands).
The study was carried out at North Estonia Medical Centre in col-
laboration	with	Helsinki	University	Hospital,	HUSLAB	 Laboratory,	
Coagulation Disorders Unit (in partnership with The Twinning 
Program of the World Federation of Hemophilia (WFH)). The study 
was performed according to the Declaration of Helsinki and was 
approved by two national ethical committees (both the Tallinn and 
Helsinki Ethical Committees on Medical Research).
2.2 | Coagulation assays
All	plasma	samples	in	question	were	analyzed	for	FVIII:C,	VWF:Ag,	
and	VWF:Ac	using	the	STA-	R	Evolution	analyzer	(Diagnostica	Stago	
S.A.S.,	Asnières	sur	Seine,	France).	The	FVIII:C	(STA	Deficient	VIII,	
STA	PTT-	A)	and	VWF:Ag	(STA	Liatest	VWF:Ag)	reagents	were	pur-
chased	from	Diagnostica	Stago	S.A.S.	 (Asnières	sur	Seine,	France).	
VWF:Ac	 was	 measured	 using	 the	 INNOVANCE	 VWF	 Ac	 reagent	
(Siemens Healthcare Diagnostics, Marburg, Germany) according to 
a previously described method.18
2.3 | Preparation of IRP
IRP	was	prepared	from	10	healthy	volunteer	plasma	samples.	Blood	
specimens	 were	 collected	 into	 3.2%	 sodium	 citrate	 tubes	 (BD	
Vacutainer,	BD	Diagnostics,	 Plymouth,	UK),	 centrifuged	 at	1500	g 
for 10 minutes at room temperature to generate platelet- free 
plasma, pooled, aliquoted into Eppendorf type tubes (composed of a 
nonactivating	plastic),	and	frozen	at	−70°C.	Prior	to	testing,	samples	
were	thawed	in	a	37°C	water	bath	(for	approximately	5	minutes)	and	
mixed thoroughly. The volunteers were healthy laboratory employ-
ees without history of hemorrhagic episodes, who were not taking 
any medication for at least 10 days before blood collection, had a 
normal coagulation screen profile and normal VWF screening assays 
results, and who provided written consent. Exclusion criteria con-
sisted of a positive personal and/or family bleeding history, inflam-
mation, pregnancy, and oral contraceptive use.
2.4 | VWF multimer method developed by Sebia
All	constituents	of	the	assay	(reagents,	instruments,	and	software)	were	
provided by Sebia (Lisses, France). Plasma samples were treated with 
sample diluent (pH 5.0 ± 0.5) and were pre- incubated for 20 minutes at 
45°C.	The	dilution	ratio	was	adapted	based	on	the	VWF:Ag	result	ac-
cording to the manufacturer’s instructions. The treated plasma samples 
were grouped into quintuplets, loaded onto Hydragel 5 von Willebrand 
multimer gels, and then subjected to a migration step using a Hydrasys 2 
system	with	the	following	parameters:	under	1	W	constant,	10°C,	con-
trolled by the Peltier effect, until 170 Vh has accumulated, and a duration 
of approximately 115 minutes. The multimers were fixed on the gel using 
rabbit origin anti- VWF antibodies and then were probed with a second- 
step immunofixation by horseradish peroxidase (HRP)- conjugated anti- 
mammalian IgG. VWF multimers were evaluated by visualization after 
coloring the gels with commercially available reagents (commercial ab-
breviation TTF1/TTF2), and densitometric gel scan/graphical curves 
were produced and visualized with Sebia Phoresis CORE software.
2.5 | Previous studies confirming the VWD  
diagnosis
Nine patients with VWD from Finland with a complex evaluation and 
follow- up at the European Haemophilia Comprehensive Care Center 
(EHCCC) in Helsinki were included. VWF multimers from 8 patients were 
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previously analyzed by SDS agarose electrophoresis, western blotting, 
and luminescent visualization recorded by photoimaging in 1 of 4 refer-
ence laboratories with long- standing expertise in VWD diagnostics: type 
1 and type 2 VWD patients were analyzed at Lund University (Malmö, 
Sweden),	Karolinska	Institute	(Stockholm,	Sweden),	or	Finnish	Red	Cross	
(Helsinki, Finland), and type 3 patients were assessed in collaboration 
with Dr. R. Schneppenheim (Hamburg, Germany).19 Genetic testing was 
performed	(i)	in	type	2B	and	2N	to	differentiate	between	platelet-	type	
VWD	 and	 hemophilia	A	 and	 (ii)	 in	 type	 3	 in	 connection	with	 genetic	
counseling, and the results were consistent with the VWD types. The 
genotypes of all type 3 VWD patients have been previously reported.19
3  | RESULTS
3.1 | VWF multimers in normal samples
The Hydragel 5 von Willebrand multiyear agarose gels were used 
to run 4 test samples and one control (reference) sample simultane-
ously. Comparative analysis of the size spectrum and banding pattern 
of VWF multimers in IRP and CNP samples on gels and the quanti-
tative results of IRP (LMW- M 15.9%, IMW- M 33.2% and HMW- M 
50.9%) and CNP (LMW- M 24.6%, IMW- M 34.7% and HMW- M 
40.7%) densitometric curves revealed a relative loss of the highest 
HMW multimers in CNP samples, probably due to the lyophilization 
process while preparing commercial plasma (Figure 1).17,20 Thus, IRP 
was preferred as control (reference) plasma in further studies.
The qualitative visual assessment of the size and distribution of 
VWF multimers in the plasma samples of four healthy subjects re-
sulted in the pattern depicted in Figure 2, where one band on the 
gel and one peak in the densitogram correspond to one multimer 
band. LMW multimers are located on the top of the gel and at the 
left side of the x- axis of the densitogram. Correspondingly, HMW 
multimers are located on the bottom of the gel and at the right side 
of the x- axis of the densitogram, and IMW multimers are located 
in-	between.	Although	there	 is	no	consensus	on	 the	definition	of	
the areas comprising LMW, IMW, and HMW multimers, for conve-
nience in interpreting the results, the multimer bands of this quar-
tet of healthy subjects were classified as follows: 1- 3 left to right 
peaks in the densitogram would represent LMW multimers, peaks 
4- 7 would represent IMW multimers, and peaks 8 and onwards 
would represent the group of HMW multimers (Figure 2). The ap-
plied classification is specific to the Sebia method and differs from 
F IGURE  1 Electrophoresis gel of IRP 
samples (tracks 1- 2), plasma samples from 
2 randomly selected healthy individuals 
(tracks 3- 4), and CNP samples (track 5). 
Densitograms of CNP and IRP
F IGURE  2 Electrophoresis gel of 
plasma samples from 4 different healthy 
individuals (tracks 1- 4) and an IRP sample 
(track 5). Densitogram of IRP
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reports in the literature (cited in the introduction), thus highlight-
ing methodological differences between previously reported in- 
house and Sebia assays.
3.2 | VWF multimers in patient samples
VWF multimer electrophoresis interpretations of 9 VWD type (1, 
2A,	2B,	2N,	or	3)	samples	from	HUSLAB,	one	type	2N	VWD	sam-
ple	from	Estonia,	and	one	hemophilia	A	sample	from	Estonia	could	
be	 successfully	 reproduced	and	were	 in	 agreement.	The	VWF:Ag,	
VWF:Ac,	 Ac/Ag	 ratio,	 FVIII:C	 results	 and	 VWF	 multimer	 pattern	
interpretations are summarized in Table 1. Several examples of the 
VWF multimer electrophoresis results of different VWD types are 
depicted in Figures 3-7. Three patients with type 1 VWD showed a 
normal VWF multimer pattern, although a relative decrease in the in-
tensity	of	the	multimer	bands	could	be	seen	(Figure	3).	As	expected,	
the	loss	of	HMW	multimers	was	seen	in	both	type	2A	(Figure	4)	and	
type	2B	(Figure	5)	VWD	samples.	Type	2N	VWD	patients	exhibited	
normal multimeric patterns (Figure 6), and no signal was detected 
in two type 3 VWD patients (Figure 7), consequently leading to un-
detectable	VWF	multimer	interpretation.	The	hemophilia	A	results	
were completely normal.
3.3 | VWF multimers in EQA samples
Throughout 2016 and 2017, the North Estonia Medical Centre 
Laboratory	 participated	 in	 seven	 EQA	 schemes	 of	 VWF	modules,	
including	VWF:Ag,	VWF:Ac,	FVIII:C,	VWF	multimers,	and	final	con-
clusion	 (interpretation)	 (The	 ECAT	 Foundation,	 the	 Netherlands).	
In all 7 surveys, VWF multimer electrophoresis interpretation and 
final interpretation of the VWD type were in agreement with expert 
opinion (Table 2).
4  | DISCUSSION
VWF multimers should not be used as a standalone test to diagnose 
VWD.21 The critical clinical utility of VWF multimers is in differenti-
ating	type	2A	and	2B	VWD	from	type	2M	(or	type	1)	VWD,12 as the 
correct classification of VWD is very important for the final diagno-
sis and treatment management.22
Unfortunately, until now, VWF multimer analysis has been per-
formed only by a limited number of expert or reference laboratories 
(only	 16%-	18%	 of	 the	 participants	 of	 The	 ECAT	 Foundation	 EQA	
surveys17), mainly because the assay is technically complex, labo-
rious, requires specially trained personnel, and is nonstandardized 
and time- consuming.14,17,23 In addition, a certain proportion of inter-
pretative errors arise due to test panels lacking the VWF multimer 
assay.5,16
The main methods in clinical use for the visualization of VWF 
multimers remain in- house- developed electrophoresis methods with 
typical overnight electrophoretic runs in agarose gels (alternatively, 
nitrocellulose or polyvinylidene difluoride) at concentrations ranging 
from 1% to 3%14,21,23 with different options for immunologically de-
tected multimer visualization (either radioactive, colorimetric, lumi-
nographic, or fluorometric methods).23 Radioactive techniques are 
potentially hazardous, but conventional nonradioactive methods 
lack sensitivity and optimal resolution power,13 potentially leading 
clinicians to misclassification of the VWD subtype.20 Luminographic 
methods are much safer and are reported to allow visualization of 
multimers with confidence and high sensitivity.13
A	 very	 important	 issue	 is	 the	 turnaround	 time	 of	 VWF	multi-
mer analysis. The above- mentioned in- house methods are time- 
consuming, and although several of them have been somewhat 
optimized, they still require dozens of hours or even 3- 4 days 
to complete.13,20 In our case, the evaluated Sebia Hydragel 5 von 
Willebrand multimer electrophoresis assay produced same- day re-
sults	 in	 only	 6	hours	 and	40	minutes.	A	 significantly	 shorter	 turn-
around time could encourage clinical laboratories to select such 
a method instead of the traditional, time- intensive procedures. 
Furthermore, in the case of analytical failure, same- day multimer 
analysis is more attractive because laboratories could repeat testing 
and release results quickly, although confirmation of the VWD type 
is not an urgent analysis.
Another	 disadvantage	 that	 many	 in-	house	 electrophoresis	
methods possess is their inability to carry out quantitative analysis 
of VWF multimers.13,20 Quantitative results can provide objective 
measures of the VWF structure to better define subtle changes in 
the VWD subtypes, such as dominant VWD type 1/2E (IIE) due to 
mutations in the D3 domain with aberrant triplet structure or the 
lack of outer bands or pronounced inner bands together with a rela-
tive decrease in LMW multimers.24,25 However, the current classifi-
cation for VWD does not consider the quantity of loss of the HMW 
multimers.20 The Sebia method provides quantitative VWF multimer 
results and allows, if desired, splitting curves into multimer subsets. 
Laboratories may be able to establish normal ranges for different 
multimer sizes (LMW, IMW, and HMW) and quantify the percent-
age of loss in abnormal samples. The quantitative performance of 
the Sebia VWF multimer assay (reference ranges, clinical decision 
limits) should be assessed in future studies. Unfortunately, the Sebia 
method does not allow the visualization of VWF multimer triplets. 
Therefore, the main difference of it, compared with noncommercial 
assays,	is	the	“quantification”	itself,	although	this	can	be	equally	ad-
dressed by the in- house methods equipped with densitometers and 
associated software. Whichever method is in use, difficult cases, 
when increased subbands or abnormal triplet structures are ob-
served, should undergo consultation with expert laboratories.
Other assays have been proposed in the literature—for example, 
direct biophysical fluorescence correlation spectroscopy—suggest-
ing the quantitative nature of the method, short analysis time, and 
potentially low cost per sample.14 However, such a method is not 
widely available for clinical laboratories, reinforcing the need for a 
rapid and commercially available VWF multimer method.
Currently, VWF multimer analysis demonstrates a relatively 
high error rate,6 mainly reflected by the rather complex nature of 
the	available	methodologies.	The	ECAT	Foundation	collected	data	
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showing substantial error rates ranging from 10% to 52%.17 The 
North	American	 Specialized	Coagulation	 Laboratory	Association	
(NASCOLA)	 showed	 an	 overall	 14.7%	 (7-	22%)	 erroneous	 sur-
vey response rate from laboratories performing in- house VWF 
multimer analysis.15	 In	our	case,	all	EQA	samples	 (including	 type	
1	and	type	2A	VWD	patients)	were	correctly	visualized	and	inter-
preted by the new commercial VWF multimer assay, demonstrat-
ing its reliability.
F IGURE  4 Electrophoresis gel of IRP 
(track	1)	and	type	2A	VWD	patient	plasma	
(track	5).	Densitograms:	IRP	vs	type	2A	
VWD patient plasma
F IGURE  5 Electrophoresis gel of IRP 
(track	1)	and	type	2B	VWD	patient	plasma	
(track	2).	Densitograms:	IRP	vs	type	2B	
VWD patient plasma
F IGURE  3 Electrophoresis gel of IRP 
(track 1) and type 1 VWD patient plasma 
(track 4). Densitograms: IRP vs type 1 
VWD patient plasma
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Another	question	is	whether	the	VWF	multimer	assay	is	needed	
in	 the	 VWD	 testing	 panel	 if	 VWF:RCo	 (alternatively	 VWF:Ac)	
and	VWF:CB	 to	VWF:Ag	 ratios	 are	used	as	 surrogate	markers	 for	
the loss of HMW multimers.7,10,11,16	 The	 UK	 Haemophilia	 Center	
Doctors	Organization	guideline	approved	by	the	British	Committee	
for Standards in Haematology recommends that such ratios be used 
to	 distinguish	 between	 types	 2A	 and	 2M	 (evidence	 level	 1B).21	 A	
VWF:RCo/VWF:Ag	 ratio	 <0.7	 should	 lead	 clinicians	 to	 look	 for	
type 2 VWD with a qualitative VWF defect and not type 1 VWD. 
However, the technical limitations of most VWF:RCo assays used 
F IGURE  6 Electrophoresis gel of IRP 
(track 1) and type 2N VWD patient plasma 
(track 4). Densitograms: IRP vs type 2N 
VWD patient plasma
F IGURE  7 Electrophoresis gel of IRP 
(track 1) and type 3 VWD patient plasma 
(track 3). Densitograms: IRP vs type 3 
VWD patient plasma
TABLE  2 Summary	of	VWF	multimer	analysis	in	EQA	samples.	Reproduced	with	permission	from	The	ECAT	Foundation	(the	Netherlands)
EQA survey No. EQA sample
Sebia VWF multimer
Conclusion on 
VWD typeInterpretation
Quantitative results, %
LMW- M IMW- M HMW- M
2016- 1 Normal control plasma Normal distribution 23.3 33.1 43.6 Not VWD
2016- 2 Type 1 VWD patient Normal distribution 18.3 30.0 51.7 Type 1 VWD
2016- 3 Type 2 VWD patient Lack of IMW- M and 
HMW- M
73.8 11.5 14.7 Type	2A	VWD
2016- 4 Type 1 VWD patient Normal distribution 10.7 26.8 62.5 Type 1 VWD
2017- 1 Normal control plasma Normal distribution 26.9 31.9 41.2 Not VWD
2017- 2 Type 2 VWD patient Lack of IMW- M and 
HMW- M
84.0 11.3 4.7 Type	2A	VWD
2017- 3 Type 1 VWD patient Normal distribution 24.7 33.0 42.3 Type 1 VWD
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in	laboratories	worldwide	make	the	VWF:RCo/VWF:Ag	ratio	unre-
liable,	especially	at	the	levels	of	VWF:Ag	less	than	15-	20	IU/dL	(%).9 
In such cases, the VWF multimer assay is very helpful to confirm or 
neglect the evidence of the loss of HMW multimers.26
Recently, the Sebia method was extensively evaluated by other 
authors, who provided positive comments on the fundamental 
consistency of the obtained data and presented reports at inter-
national meetings.27 The same group of scientists additionally 
published a chapter on VWF multimers in the book available from 
Springer	Science	+	Business	Media	 (Hemostasis	 and	Thrombosis:	
Methods	and	Protocols,	Methods	in	Molecular	Biology,	vol.	1646).	
This paper describes the multimer methodology developed by 
Sebia in detail.28
5  | CONCLUSIONS
The new commercial VWF multimer assay (Hydragel 5 von 
Willebrand multimers; Sebia, Lisses, France) may represent a good 
alternative to traditional in- house assays. The Sebia method is 
easy to perform and can be successfully implemented in any clini-
cal laboratory for second- stage evaluation of VWD. This method 
is a semi- automated agarose gel electrophoresis assay with ready- 
to- use gel and reagents, simple to carry out, and rapid (same- 
day results) compared with other (mainly in- house) methods. 
Visualization of the multimer distribution and densitometric analy-
sis, together with the applied LMW, IMW, and HMW multimer clas-
sification, provide adequate resolution to correctly classify types 
1,	 2A,	 2B,	 and	 3	 VWD	 cases.	 This	 new	 assay	 can	 be	 processed	
in routine use on a classical Sebia Hydrasys 2 multiparameter in-
strument. Furthermore, there is no need for additional training of 
laboratory technicians, and all of the main steps and instrument 
software are easily understandable and operated in a similar man-
ner as other Sebia electrophoresis techniques (ie, serum/urine pro-
tein electrophoresis, immunofixation). Only the interpretation of 
the results should be carried out by or in consultation with experts. 
Nevertheless, the utility and value of this commercial method as 
an alternative for in- house assays must still be confirmed in fu-
ture	analyses.	Evidence	should	be	collected	by	the	EQA	organizers	
who have a substantial amount of data on the available methods. 
Likewise, larger- scale methods and comparison studies should be 
carried out because the small number of patients in our study was 
a major limitation.
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